---
title: "Medicamen Organics Ltd (MEDIORG) — Share Price, Financials & Analysis"
symbol: "MEDIORG"
company: "Medicamen Organics Ltd"
canonical: "https://tapetide.com/stocks/MEDIORG"
isin: "INE0PE401018"
nse_symbol: "MEDIORG"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 29.14
generated_at: "2026-09-13T19:38:49.864Z"
---

# Medicamen Organics Ltd (MEDIORG)

Canonical page: https://tapetide.com/stocks/MEDIORG

## Company

- **NSE Symbol:** MEDIORG
- **ISIN:** INE0PE401018
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 2024-06-28
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** medicamenorganics.com

## About

Incorporated in 1995, Medicamen Organics Ltd develops, manufactures, and distributes a broad range of  pharmaceutical dosages including generic dosage[1]

## Latest Price

- **Price:** ₹23.95
- **Change:** -1.25 (-4.96%)
- **Open:** ₹23.95
- **Day High:** ₹25
- **Day Low:** ₹23.95
- **Previous Close:** ₹25.2
- **Volume:** 12000
- **As Of:** 2026-09-11T08:37:42+00:00

## Key Fundamentals

Observed at 2026-09-11T04:50:12.438623Z.

- **Market Cap:** ₹29.14 Cr
- **Classification:** SME
- **P/E (reported):** -9.3
- **Book Value:** ₹25.69
- **Price to Book:** 0.98
- **Dividend Yield:** 0%
- **ROE:** 13.28%
- **ROCE:** 18.54%
- **Debt to Equity:** 0.5
- **Revenue (yearly):** ₹22.63 Cr
- **Net Income:** ₹-5.28 Cr
- **EBITDA:** ₹-3.75 Cr
- **52-Week High:** ₹38
- **52-Week Low:** ₹19.1
- **RSI (14):** 51.81

## Tapetide Score

- **Score:** 31 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 2.7 (of 4473 scored stocks)
- **Confidence:** 81%
- **Data coverage:** 62%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 24.08 | 9% |
| growth | 4.85 | 9% |
| momentum | 76.45 | 12% |
| ownership | 27.81 | 24% |
| quality | 36.01 | 22% |
| valuation | 40.48 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Stock is trading at 1.01 times its book value

### Weaknesses

- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -6.38%
- Company has a low return on equity of 3.01% over last 3 years.
- Company might be capitalizing the interest cost
- Company has high debtors of 300 days.
- Working capital days have increased from 144 days to 223 days

## Growth Rates

| Metric | 1Y | 3Y | 5Y |
| --- | --- | --- | --- |
| cash flow growth | -24.04% | -212.94% | -182.55% |
| ebitda margin growth | -194.61% | -187.82% | — |
| net income growth | -232% | -303.08% | — |
| revenue growth | -40.91% | -3.65% | — |
| roce | -38.67% | -38.67% | — |
| roe | -22.79% | 15.24% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- |
| Sales | 13.95 | 16.61 | 21.58 | 17.85 | 4.78 |
| Expenses | 11.62 | 13.88 | 17.73 | 14.43 | 11.95 |
| Operating Profit | 2.33 | 2.73 | 3.85 | 3.42 | -7.17 |
| OPM % | 16.7 | 16.44 | 17.84 | 19.16 | -150 |
| Other Income | 0.01 | 0.04 | 0.05 | 0.06 | 0.02 |
| Interest | 0.36 | 0.22 | 0.29 | 0.33 | 0.38 |
| Depreciation | 0.36 | 0.36 | 0.37 | 0.41 | 0.48 |
| Profit before tax | 1.62 | 2.19 | 3.24 | 2.74 | -8.01 |
| Tax % | 22.84 | 30.59 | 21.6 | 25.55 | -24.47 |
| Net Profit | 1.26 | 1.51 | 2.54 | 2.04 | -6.06 |
| EPS in Rs | 1.47 | 1.29 | 2.17 | 1.74 | -4.98 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Sales | 25.27 | 38.19 | 22.63 |
| Expenses | 20.53 | 31.58 | 26.38 |
| Operating Profit | 4.74 | 6.61 | -3.75 |
| OPM % | 18.76 | 17.31 | -16.57 |
| Other Income | 1.07 | 0.1 | 0.08 |
| Interest | 0.65 | 0.54 | 0.71 |
| Depreciation | 0.72 | 0.74 | 0.9 |
| Profit before tax | 4.44 | 5.43 | -5.28 |
| Tax % | 40.77 | 25.41 | -23.86 |
| Net Profit | 2.62 | 4.05 | -4.02 |
| EPS in Rs | 3.05 | 3.46 | -3.3 |
| Dividend Payout % | 0 | 0 | 0 |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Equity Capital | 8.6 | 11.7 | 12.17 |
| Reserves | 6.66 | 18.43 | 16.56 |
| Borrowings | 12.66 | 12.35 | 14.3 |
| Other Liabilities | 10.52 | 16.73 | 8.6 |
| Total Liabilities | 38.44 | 59.21 | 51.63 |
| Fixed Assets | 10.35 | 10.13 | 13.37 |
| CWIP | 0.15 | 2.22 | 0.09 |
| Investments | 0 | 0 | 0 |
| Other Assets | 27.94 | 46.86 | 38.17 |
| Total Assets | 38.44 | 59.21 | 51.63 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Cash from Operating Activity | -3.66 | -4.54 | -4.6 |
| Cash from Investing Activity | -0.34 | -2.35 | -1.72 |
| Cash from Financing Activity | 4.01 | 10.47 | 3.48 |
| Net Cash Flow | 0.01 | 3.58 | -2.83 |
| Free Cash Flow | -4.01 | -6.99 | -6.34 |
| CFO/OP | -73 | -67 | 119 |

### Ratios

| Item | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- |
| Debtor Days | 241.21 | 247.06 | 300.32 |
| Inventory Days | 244.39 | 228.39 | 243.18 |
| Days Payable | 281.81 | 356.77 | 128.52 |
| Cash Conversion Cycle | 203.8 | 118.69 | 414.98 |
| Working Capital Days | 74.24 | 135.14 | 222.74 |
| ROCE % | — | 16.88 | -10.66 |

## Shareholding Pattern

### Quarterly

| Category | Jun 2024 | Sep 2024 | Mar 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- |
| Promoters | 59.69% | 59.69% | 59.73% | 59.73% | 59.73% | 54.89% |
| FIIs | 0% | 0% | 0% | 0% | 0.07% | 0.05% |
| DIIs | 0.27% | 0.07% | 0.1% | 0% | 1.64% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 13.85% | 28.27% | 28.79% | 30.58% | 30.79% | 24.17% |
| Others | 26.19% | 11.97% | 11.38% | 9.69% | 7.78% | 20.89% |
| No. of Shareholders | 34 | 379 | 460 | 507 | 540 | 508 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Sell
- **Buy / Neutral / Sell:** 2 / 7 / 10

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 24.43 | Sell |
| EMA (10) | 24.78 | Sell |
| SMA (20) | 24.67 | Sell |
| EMA (20) | 24.75 | Sell |
| SMA (50) | 24.57 | Sell |
| EMA (50) | 24.66 | Sell |
| SMA (100) | 24.84 | Sell |
| EMA (100) | 24.96 | Sell |
| SMA (200) | 25.64 | Sell |
| EMA (200) | 26.68 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 46.67 | Neutral |
| MACD (12,26,9) | 0.03 | Buy |
| Stochastic (14,3,3) | 63.49 | Neutral |
| ADX (14) | 11.5 | Neutral |
| Williams %R (14) | -66.67 | Neutral |
| ATR (14) | 1.18 | High Volatility |
| ROC (12) | 3.46 | Buy |
| Stoch RSI (14) | 31.62 | Neutral |
| UO (7,14,28) | 36.12 | Neutral |

## Filings & Documents

### Other Documents

| Date | Document |
| --- | --- |
| 9 June 2026 - Allotted 27.14 lakh shares and 11.86 lakh warrants for ₹13.65 crore on June 9, 2026. | [Committee Meeting Updates 9 June 2026 - Allotted 27.14 lakh shares and 11.86 lakh warrants for ₹13.65 crore on June 9, 2026.](https://nsearchives.nseindia.com/corporate/MEDICAMENORGANICS_09062026131056_Disclosure_for_the_allotment_of_equity_shares_and_warrants.pdf) |
| 9 Jun - Auditor certified ₹12.29 crore preferential allotment of 39 lakh shares and warrants on June 9, 2026. | [General Updates 9 Jun - Auditor certified ₹12.29 crore preferential allotment of 39 lakh shares and warrants on June 9, 2026.](https://nsearchives.nseindia.com/corporate/MEDICAMENORGANICS_09062026134943_Disclosure_of_Auditors_Certificate_for_the_reciept_of_monies.pdf) |
| 9 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no demat/remat requests processed. | [Certificate under SEBI (Depositories and Participants) Regulations, 2018 9 Jul - Submitted Regulation 74(5) certificate for quarter ended June 30, 2026; no demat/remat requests processed.](https://nsearchives.nseindia.com/corporate/MEDICAMENORGANICS_09072026122422_Disclosure.pdf) |
| 9 April 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written … | [Price movement 9 April 2026 - Investors have latest relevant information about the company and to inform the market place so that the interest of the investors is safeguarded, has written …](https://www.nseindia.com/companies-listing/corporate-filings-announcements?symbol=MEDIORG&tabIndex=sme) |
| 9 April 2026 - EGM approved capital increase, 20 lakh equity issue, 11.86 lakh warrants, and loan conversion into 7.14 lakh shares. | [Shareholders meeting 9 April 2026 - EGM approved capital increase, 20 lakh equity issue, 11.86 lakh warrants, and loan conversion into 7.14 lakh shares.](https://nsearchives.nseindia.com/corporate/MEDICAMENORGANICS_09042026190228_Intimation_EGM_Proceeding_Signed.pdf) |
| 8 May 2026 - Company clarifies price recomputation and lock-in for preferential shares and warrants after EGM approvals. | [Updates 8 May 2026 - Company clarifies price recomputation and lock-in for preferential shares and warrants after EGM approvals.](https://nsearchives.nseindia.com/corporate/MEDICAMENORGANICS_08052026134601_Disclosure.pdf) |
| 31 Aug - FY2025-26 annual report filed; 31st AGM on September 25, 2026 via VC/OAVM. | [Shareholders meeting 31 Aug - FY2025-26 annual report filed; 31st AGM on September 25, 2026 via VC/OAVM.](https://nsearchives.nseindia.com/corporate/MEDICAMENORGANICS_31082026185759_SUBMISSIONOFREPORTANDNOTICE.pdf) |
| 30 May 2026 - Company says Annual Secretarial Compliance Report not applicable for FY ended March 31, 2026 due SME listing. | [Updates 30 May 2026 - Company says Annual Secretarial Compliance Report not applicable for FY ended March 31, 2026 due SME listing.](https://nsearchives.nseindia.com/corporate/MEDICAMENORGANICS_30052026115435_Reg24A_nonapplicability.pdf) |
| 30 Aug - Newspaper ads published for 31st AGM on September 25, 2026; notice and annual report available online. | [Copy of Newspaper Publication 30 Aug - Newspaper ads published for 31st AGM on September 25, 2026; notice and annual report available online.](https://nsearchives.nseindia.com/corporate/MEDICAMENORGANICS_30082026133746_PRIORNEWSPAPERINTIMATION.pdf) |
| 3 June 2026 - Ritu Gupta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. | [Disclosure under SEBI Takeover Regulations 3 June 2026 - Ritu Gupta has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.](https://nsearchives.nseindia.com/corporate/team_sandeshc_20052026132134_10.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Annual Report 2026 from nse](https://archives.nseindia.com/annual_reports/SME_AR_30926_MEDIORG_2025_2026_A_14722375_31082026190950.pdf) |
| from nse | [Annual Report 2025 from nse](https://archives.nseindia.com/annual_reports/SME_AR_28196_MEDIORG_2024_2025_A_37882764_02092025185839.pdf) |
| from nse | [Annual Report 2024 from nse](https://archives.nseindia.com/annual_reports/SME_AR_26302_MEDIORG_2023_2024_0310202414145.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2024 | [Concall - Oct 2024](https://nsearchives.nseindia.com/corporate/MEDIORG_22102024190822_Regulation30InvestorPresentation.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://nsearchives.nseindia.com/corporate/MEDIORG_25112024203941_SubmissionofTranscriptH1FY25.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://nsearchives.nseindia.com/corporate/MEDICAMENORGANICS_10062025173415_Final_Intimation_10062025_Transcript.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:38:49.864Z.